FOCL Share Price Performance
US$5.44
3.91 (257.57%)
36.1% undervalued intrinsic discount
US$8.50
Fair Value
Price US$5.44
AnalystConsensusTarget US$8.50
LuckyII US$10.74
AnalystHighTarget US$10.00
Fair ValueUS$8.50
Share Pricen/a
EDAP TMS S.A. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
FOCL Community Narratives
AN
Fair Value
·Fair Value US$8.5 36.1% undervalued intrinsic discount
Global HIFU Adoption Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
LU
Fair Value
·Fair Value US$10.74 49.4% undervalued intrinsic discount
A surgeon's dream
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$10 45.7% undervalued intrinsic discount
HIFU And Focal One Will Transform Care For Aging Patients
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
A surgeon's dream
One main problem in any surgery is access to the operative site: This means cutting through and bleeding from healthy tissue with infections, scars, pain, prolonged hospital stays and costs. Focal therapy with HIFU takes this burden out of the equation, which has been any surgeon's dream for centuries.Read more
Global HIFU Adoption Will Open New Markets
Key Takeaways Rapid adoption of minimally invasive HIFU technology and improved reimbursement is driving market expansion, higher procedure revenue, and deeper hospital network penetration. New therapeutic indications, growing recurring revenue, and strengthened global operations position EDAP for sustained multi-year growth and greater earnings visibility.Read more
AN
US$8.5
36.1% undervalued intrinsic discount
Fair Value
Profit Margin
11.77%
Future PE
27.45x
Price in 2029
US$10.7
Tariffs And Delays Will Hinder Progress Though Trials Offer Hope
EDAP TMS is trying to ride rising demand for less invasive urology treatments, but it may struggle if insurance approvals keep lagging and hospitals tighten spending. Add in reliance on one flagship system and possible trade and supply disruptions, and there’s a lot that could slow the company’s progress even as clinical trial results look encouraging.Read more
AN
US$3
81.2% overvalued intrinsic discount
Fair Value
Profit Margin
11.88%
Future PE
12.35x
Price in 2029
US$3.79
HIFU And Focal One Will Transform Care For Aging Patients
A lesser-known use for EDAP’s Focal One system could spread faster than many expect, potentially turning the company into a much bigger player in minimally invasive care. But the story hinges on hospitals, regulators, and insurers staying onside—any slowdown there could quickly derail growth.Read more
AN
US$10
45.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
28.68x
Price in 2029
US$12.66
Trending Discussion
No trending discussion available.
Recently Updated Narratives
LU
A surgeon's dream
Fair Value: US$10.74 49.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FOCL: Prostate Cancer Ultrasound Adoption Will Drive Longer Term Upside
Fair Value: US$8.5 36.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FOCL: Execution And Margin Risks Will Limit Upside Versus Current Pricing
Fair Value: US$3 81.2% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
EDAP TMS S.A. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.82
- 43.41%
- -41.70%
- 240.6%
About FOCL
- Founded
- 1979
- Employees
- 289
- CEO
- WebsiteView website
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
